The integration of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) into Major Depressive Disorder (MDD) treatment shows promise, with studies indicating improved response and remission rates. However, the use of NSAIDs presents challenges including potential side effects, drug interactions, and variability in patient response. Regular patient monitoring and personalized treatment strategies can mitigate these risks. Additionally, further research is needed to understand the underlying mechanisms linking inflammation, NSAIDs, and MDD, and to identify biomarkers that can predict a patient’s response to NSAIDs. Ethical and practical considerations, such as responsible NSAID implementation and understanding their safety profile, are also crucial. Despite these challenges, the potential benefits of NSAIDs in MDD make this an exciting area of research.